Amundi Has $500.89 Million Stock Holdings in Cencora, Inc. $COR

Amundi boosted its stake in Cencora, Inc. (NYSE:COR) by 17.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,720,278 shares of the company’s stock after purchasing an additional 249,742 shares during the period. Amundi’s holdings in Cencora were worth $500,893,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. Intrust Bank NA bought a new position in shares of Cencora in the 1st quarter valued at $225,000. Goldman Sachs Group Inc. increased its holdings in Cencora by 9.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after purchasing an additional 154,311 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Cencora by 1.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,045,819 shares of the company’s stock worth $290,832,000 after purchasing an additional 17,948 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Cencora by 10.3% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,077 shares of the company’s stock valued at $85,395,000 after purchasing an additional 28,791 shares during the last quarter. Finally, AlphaCore Capital LLC boosted its stake in shares of Cencora by 15.7% during the first quarter. AlphaCore Capital LLC now owns 1,845 shares of the company’s stock valued at $513,000 after purchasing an additional 251 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total value of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares in the company, valued at approximately $24,105,113.44. This trade represents a 7.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,640 shares of company stock valued at $14,099,338 in the last quarter. 10.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the company. Robert W. Baird upped their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. TD Cowen boosted their target price on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, November 10th. UBS Group upped their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Finally, Mizuho boosted their price objective on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Performance

Shares of Cencora stock opened at $339.28 on Friday. The business has a 50-day moving average price of $340.04 and a two-hundred day moving average price of $309.49. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $377.54. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The company has a market cap of $65.82 billion, a P/E ratio of 42.68, a PEG ratio of 1.60 and a beta of 0.63.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the prior year, the company earned $3.34 EPS. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.